What is Erste Group Bank’s Estimate for NVO FY2027 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Research analysts at Erste Group Bank upped their FY2027 earnings estimates for Novo Nordisk A/S in a note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.24 per share for the year, up from their prior estimate of $3.20. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.39 per share.

NVO has been the topic of a number of other reports. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.81.

Novo Nordisk A/S Stock Performance

NVO stock opened at $47.22 on Monday. The company has a 50 day moving average price of $47.15 and a 200 day moving average price of $44.72. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock has a market capitalization of $210.82 billion, a PE ratio of 11.54, a price-to-earnings-growth ratio of 4.35 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%.

Institutional Investors Weigh In On Novo Nordisk A/S

Large investors have recently made changes to their positions in the stock. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $25,000. WealthCollab LLC increased its holdings in Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S during the 4th quarter worth about $29,000. Transamerica Financial Advisors LLC raised its stake in shares of Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after purchasing an additional 403 shares during the period. Finally, Quaker Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 186.0% in the 4th quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock valued at $31,000 after purchasing an additional 400 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be paid a $0.5786 dividend. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s payout ratio is presently 42.79%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk announced that Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, is now available in the United States. The launch expands the company’s diabetes portfolio and could support future sales growth. Novo Nordisk’s Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
• Positive Sentiment: Novo Nordisk and Amazon Web Services will collaborate on drug discovery, with AWS serving as the company’s preferred global cloud and strategic AI partner. A London innovation hub and expanded use of AI tools could accelerate drug targeting, therapy design and clinical-data analysis. Novo Nordisk, Amazon Web Services Collaborate to Advance Drug Discovery for Chronic Diseases
• Positive Sentiment: Erste Group Bank raised its FY2026 earnings-per-share forecast for Novo Nordisk to $3.27 from $3.20. Although the estimate remains below the broader $3.39 consensus, the increase signals improving analyst expectations. Erste Group Bank raises Novo Nordisk earnings estimate
• Positive Sentiment: Analysts have set an average price target of $65.56 for NVO, well above the recent share price near $47, suggesting substantial perceived upside if the company executes on its diabetes, obesity and pipeline opportunities. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Neutral Sentiment: Novo Nordisk supplied semaglutide for Veru’s fully enrolled Phase 2b weight-loss trial. Interim results are expected in the first quarter of 2027, so the collaboration offers potential long-term value but no immediate financial catalyst. Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Progress
• Neutral Sentiment: European-listed stocks trading as U.S. depositary receipts were broadly higher, providing a supportive backdrop for NVO, though the move was market-wide rather than specific to Novo Nordisk. European Equities Traded in the US as American Depositary Receipts Rise
• Negative Sentiment: Analyst comparisons with Eli Lilly highlight continued competitive pressure in obesity drugs. Lilly’s perceived advantages in clinical execution, manufacturing and commercial momentum could weigh on Novo Nordisk’s market-share and growth outlook. Eli Lilly vs. Novo Nordisk in the obesity market
• Negative Sentiment: Further coverage frames GLP-1 manufacturing capacity as an increasingly important competitive moat, keeping investor focus on whether Novo Nordisk can match Lilly’s supply and demand execution. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.